PTAB grants IPR of Regeneron Eylea patents
11-11-2021
Nicox verifies patent extension eligibility at USPTO
22-04-2021
T. Schneider / Shutterstock.com
Licensing partners aim to prevent the introduction of a proposed eye drop generic treatment before the expiration of four patents.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bausch & Lomb, Nicox, Gland Pharma, New Jersey, patents
